| Year |
Citation |
Score |
| 2024 |
Knapp CP, Fallon B, Kortagere S, Waterhouse BD, Floresco SB, Navarra RL. SK609, a novel dopamine D3 receptor agonist and norepinephrine transporter blocker with putative pro-cognitive actions, does not induce psychostimulant-like increases in risky choice during probabilistic discounting. Psychopharmacology. PMID 39630237 DOI: 10.1007/s00213-024-06727-1 |
0.556 |
|
| 2024 |
Knapp CP, Papadopoulos E, Loweth JA, Raghupathi R, Floresco SB, Waterhouse BD, Navarra RL. Sex-dependent perturbations in risky choice behavior and prefrontal tyrosine hydroxylase levels induced by repetitive mild traumatic brain injury. Behavioural Brain Research. 115244. PMID 39241835 DOI: 10.1016/j.bbr.2024.115244 |
0.559 |
|
| 2024 |
Knapp CP, Papadopoulos E, Loweth JA, Raghupathi R, Floresco SB, Waterhouse BD, Navarra RL. Perturbations in Risk/Reward Decision Making and Frontal Cortical Catecholamine Regulation Induced by Mild Traumatic Brain Injury. Behavioural Brain Research. 115002. PMID 38636779 DOI: 10.1016/j.bbr.2024.115002 |
0.545 |
|
| 2018 |
Waterhouse BD, Navarra RL. The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Brain Research. PMID 30179606 DOI: 10.1016/J.Brainres.2018.08.032 |
0.619 |
|
| 2018 |
Navarra RL, Waterhouse BD. Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Brain Research. PMID 29935154 DOI: 10.1016/J.Brainres.2018.06.027 |
0.668 |
|
| 2018 |
Navarra R, Waterhouse B. "What have we GANEd?" A theoretical construct to explain experimental evidence for noradrenergic regulation of sensory signal processing. The Behavioral and Brain Sciences. 39: e219. PMID 28347394 DOI: 10.1017/S0140525X15001909 |
0.597 |
|
| 2016 |
Navarra RL, Clark BD, Gargiulo AT, Waterhouse BD. Methylphenidate Enhances Early Stage Sensory Processing and Rodent Performance of a Visual Signal Detection Task. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27910862 DOI: 10.1038/Npp.2016.267 |
0.683 |
|
| 2013 |
Navarra RL, Clark BD, Zitnik GA, Waterhouse BD. Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats. Experimental and Clinical Psychopharmacology. 21: 363-74. PMID 24099357 DOI: 10.1037/A0033563 |
0.552 |
|
| 2010 |
Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, et al. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. The Journal of Pharmacology and Experimental Therapeutics. 332: 190-201. PMID 19828876 DOI: 10.1124/Jpet.109.157388 |
0.363 |
|
| 2009 |
Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-GarcÃa S, Reinders JH, Neut Mv, McCreary A, Kruse CG, Sullivan K, Pruthi F, Lai M, ... ... Navarra RL, et al. Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 19: 5552-5. PMID 19720528 DOI: 10.1016/J.Bmcl.2009.08.050 |
0.305 |
|
| 2009 |
Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 331: 574-90. PMID 19661377 DOI: 10.1124/Jpet.109.155994 |
0.355 |
|
| 2009 |
Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology. 204: 37-48. PMID 19107466 DOI: 10.1007/S00213-008-1433-Z |
0.314 |
|
| 2008 |
Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, et al. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. The Journal of Pharmacology and Experimental Therapeutics. 327: 827-39. PMID 18753411 DOI: 10.1124/Jpet.108.136580 |
0.394 |
|
| 2008 |
Liu F, Day M, Muñiz LC, Bitran D, Arias R, Revilla-Sanchez R, Grauer S, Zhang G, Kelley C, Pulito V, Sung A, Mervis RF, Navarra R, Hirst WD, Reinhart PH, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nature Neuroscience. 11: 334-43. PMID 18297067 DOI: 10.1038/Nn2057 |
0.313 |
|
| 2008 |
Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M. The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test Behavioural Brain Research. 188: 412-415. PMID 18191235 DOI: 10.1016/J.Bbr.2007.11.016 |
0.37 |
|
| 2008 |
Navarra R, Graf R, Huang Y, Logue S, Comery T, Hughes Z, Day M. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test Progress in Neuro-Psychopharmacology and Biological Psychiatry. 32: 34-41. PMID 17714843 DOI: 10.1016/J.Pnpbp.2007.06.017 |
0.457 |
|
| 2007 |
Day M, Pan JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochemical Pharmacology. 73: 1123-34. PMID 17214974 DOI: 10.1016/J.Bcp.2006.12.004 |
0.457 |
|
| Show low-probability matches. |